Optimized production and concentration of lentiviral vectors containing large inserts

Journal of Gene Medicine

Volumn 9, Issue 7, 2007, Pages 579-584

  al Yacoub, Nadya ^a   Romanowska, Malgorzata ^a   Haritonova, Natalie ^a   Foerster, John ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Lentivirus; Titer; Ultracentrifugation; Virus production

Indexed keywords

LENTIVIRUS VECTOR;

ARTICLE; CONTROLLED STUDY; DNA PACKAGING; GENE INSERTION; GENE STRUCTURE; GENE TECHNOLOGY; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; ULTRACENTRIFUGATION; VIROGENESIS; VIRUS REPLICATION; VIRUS TITRATION;

DNA; GENETIC VECTORS; HELA CELLS; HUMANS; LENTIVIRUS; TRANSFECTION; ULTRACENTRIFUGATION;

LENTIVIRUS;

EID: 34447581119     PISSN: 1099498X     EISSN: 15212254     Source Type: Journal    
DOI: 10.1002/jgm.1052     Document Type: Article

References (27)

1. Mangeat B, Trono D. Lentiviral vectors and antiretroviral intrinsic immunity. Hum Gene Ther 2005; 16: 913-920.
2. Fassler R. Lentiviral transgene vectors. EMBO Rep 2004; 5: 28-29.
3. Biffi A, Naldini L. Gene therapy of storage disorders by retroviral and lentiviral vectors. Hum Gene Ther 2005; 16: 1133-1142.
4. Dull T, Zufferey R, Kelly M, et al. A third-generation lentivirus vector with a conditional packaging system. J Virol 1998; 72: 8463-8471.
5. Cockrell AS, Ma H, Fu K, McCown TJ, Kafri T. A trans-lentiviral packaging cell line for high-titer conditional self-inactivating HIV-1 vectors. Mol Ther 2006; 14: 276-284.
6. Ni Y, Sun S, Oparaocha I, et al. Generation of a packaging cell line for prolonged large-scale production of high-titer HIV-1-based lentiviral vector. J Gene Med 2005; 7: 818-834.
7. Xu K, Ma H, McCown TJ, Verma IM, Kafri T. Generation of a stable cell line producing high-titer self-inactivating lentiviral vectors. Mol Ther 2001; 3: 97-104.
8. Pacchia. AL, Adelson ME, Kaul M, Ron Y, Dougherty JP. An inducible packaging cell system for safe, efficient lentiviral vector production in the absence of HIV-1 accessory proteins. Virology 2001; 282: 77-86.
9. Farson D, Witt R, McGuinness R, et al. A new-generation stable inducible packaging cell line for lentiviral vectors. Hum Gene Ther 2001; 12: 981-997.
10. Zhang B, Xia HQ, Cleghorn G, Gobe G, West M, Wei MQ. A highly efficient and consistent method for harvesting large volumes of high-titre lentiviral vectors. Gene Ther 2001; 8: 1745-1751.
11. Sena-Esteves M, Tebbets JC, Steffens S, Crombleholme T, Flake AW. Optimized large-scale production of high titer lentivirus vector pseudotypes. J Virol Methods 2004; 122: 131-139.
12. Sakoda T, Kasahara N, Hamamori Y, Kedes L. A high-titer lentiviral production system mediates efficient transduction of differentiated cells including beating cardiac myocytes. J Mol Cell Cardiol 1999; 31: 2037-2047.
13. Mitta B, Rimann M, Fussenegger M. Detailed design and comparative analysis of protocols for optimized production of high-performance HIV-1-derived lentiviral particles. Metab Eng 2005; 7: 426-436.
14. Logan AC, Nightingale SJ, Haas DL, Cho GJ, Pepper KA, Kohn DB. Factors influencing the titer and infectivity of lentiviral vectors. Hum Gene Ther 2004; 15: 976-988.
15. Klages N, Zufferey R, Trono D. A stable system for the high-titer production of multiply attenuated lentiviral vectors. Mol Ther 2000; 2: 170-176.
16. Kumar M, Keller B, Makalou N, Sutton RE. Systematic determination of the packaging limit of lentiviral vectors. Hum Gene Ther 2001; 12: 1893-1905.
17. Reiser J. Production and concentration of pseudotyped HIV-1-based gene transfer vectors. Gene Ther 2000; 7: 910-913.
18. Nesbeth D, Williams SL, Chan L, et al. Metabolic biotinylation of lentiviral pseudotypes for scalable paramagnetic microparticle-dependent manipulation. Mol Ther 2006; 13: 814-822.
19. Rubinson DA, Dillon CP, Kwiatkowski AV, et al. A lentivirus-based system to functionally silence genes in primary mammalian cells, stem cells and transgenic mice by RNA interference. Nat Genet 2003; 33: 401-406.
20. Szulc J, Wiznerowicz M, Sauvain MO, Trono D, Aebischer P. A versatile tool for conditional gene expression and knockdown. Nat Methods 2006; 3: 109-116.
21. Haack K, Cockrell AS, Ma H, et al. Transactivator and structurally optimized inducible lentiviral vectors. Mol Ther 2004; 10: 585-596.
22. Koponen JK, Kankkonen H, Kannasto J, et al. Doxycycline-regulated lentiviral vector system with a novel reverse transactivator rtTA2S-M2 shows a tight control of gene expression in vitro and in vivo. Gene Ther 2003; 10: 459-466.
23. Wiznerowicz M. Protocol for production of lentiviral vectors in 293T cells. Available: http://tronolab.epfl.ch/webdav/site/tronolab/shared/ protocols/protocols_lentivectors.html: tronolab.eplf.ch; 2006; (last update).
24. Lois C, Refaeli Y, Qin XF, Van Parijs L. Retroviruses as tools to study the immune system. Curr Opin Immunol 2001; 13: 496-504.
25. Blesch A. Lentiviral and MLV based retroviral vectors for ex vivo and in vivo gene transfer. Methods 2004; 33: 164-172.
26. Karolewski BA, Watson DJ, Parente MK, Wolfe JH. Comparison of transfection conditions for a lentivirus vector produced in large volumes. Hum Gene Ther 2003; 14: 1287-1296.
27. Yang J, Friedman MS, Bian H, Crofford IJ, Roessler B, McDonagh KT. Highly efficient genetic transduction of primary human synoviocytes with concentrated retroviral supernatant. Arthritis Res 2002; 4: 215-219.